PedAM

Pediatric Disease Annotations & Medicines


	thrombophlebitis

Disease ID	1361
Disease	thrombophlebitis
Definition	Inflammation of a vein associated with a blood clot (THROMBUS).
Synonym	thrombophlebitides thrombophlebitis (disorder) thrombophlebitis [disease/finding] thrombophlebitis nos thrombophlebitis nos (disorder) thrombophlebitis, nos
DOID	DOID:3875
UMLS	C0040046
MeSH	D013924
SNOMED-CT	SNOMEDCT_US_2016_09_01:64156001
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:22) C0040053 \| thrombosis \| 3 C0034065 \| pulmonary embolism \| 3 C0343525 \| lemierre syndrome \| 2 C0042345 \| varicose vein \| 2 C0042485 \| venous insufficiency \| 1 C0018916 \| hemangioma \| 1 C0699791 \| gastric carcinoma \| 1 C0029443 \| osteomyelitis \| 1 C0152965 \| staphylococcal bacteremia \| 1 C0018920 \| cavernous hemangioma \| 1 C0038539 \| subdural empyema \| 1 C0235974 \| pancreatic cancer \| 1 C0024904 \| mastoiditis \| 1 C0007642 \| cellulitis \| 1 C0013595 \| eczema \| 1 C0155626 \| acute mi \| 1 C0085693 \| acute appendicitis \| 1 C0456909 \| blindness \| 1 C0019069 \| hemophilia \| 1 C0729771 \| throat infection \| 1 C0037199 \| sinusitis \| 1 C0018099 \| gout \| 1
Curated Gene	(Waiting for update.)
Inferring Gene	(Waiting for update.)
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:73) 350 \| APOH \| DISEASES 3053 \| SERPIND1 \| DISEASES 9567 \| GTPBP1 \| DISEASES 5020 \| OXT \| DISEASES 2158 \| F9 \| DISEASES 5327 \| PLAT \| DISEASES 973 \| CD79A \| DISEASES 5054 \| SERPINE1 \| DISEASES 5917 \| RARS \| DISEASES 6402 \| SELL \| DISEASES 5552 \| SRGN \| DISEASES 27112 \| FAM155B \| DISEASES 2161 \| F12 \| DISEASES 1401 \| CRP \| DISEASES 7274 \| TTPA \| DISEASES 25833 \| POU2F3 \| DISEASES 1588 \| CYP19A1 \| DISEASES 10017 \| BCL2L10 \| DISEASES 7450 \| VWF \| DISEASES 6403 \| SELP \| DISEASES 8034 \| SLC25A16 \| DISEASES 5286 \| PIK3C2A \| DISEASES 3263 \| HPX \| DISEASES 6652 \| SORD \| DISEASES 5921 \| RASA1 \| DISEASES 10667 \| FARS2 \| DISEASES 4841 \| NONO \| DISEASES 9510 \| ADAMTS1 \| DISEASES 5739 \| PTGIR \| DISEASES 213 \| ALB \| DISEASES 2147 \| F2 \| DISEASES 5340 \| PLG \| DISEASES 79966 \| SCD5 \| DISEASES 274 \| BIN1 \| DISEASES 9377 \| COX5A \| DISEASES 5345 \| SERPINF2 \| DISEASES 7791 \| ZYX \| DISEASES 55742 \| PARVA \| DISEASES 2152 \| F3 \| DISEASES 1576 \| CYP3A4 \| DISEASES 23583 \| SMUG1 \| DISEASES 5493 \| PPL \| DISEASES 10019 \| SH2B3 \| DISEASES 55124 \| PIWIL2 \| DISEASES 9652 \| TTC37 \| DISEASES 2157 \| F8 \| DISEASES 5788 \| PTPRC \| DISEASES 462 \| SERPINC1 \| DISEASES 2153 \| F5 \| DISEASES 54834 \| GDAP2 \| DISEASES 282991 \| BLOC1S2 \| DISEASES 959 \| CD40LG \| DISEASES 25844 \| YIPF3 \| DISEASES 3108 \| HLA-DMA \| DISEASES 2155 \| F7 \| DISEASES 4524 \| MTHFR \| DISEASES 1854 \| DUT \| DISEASES 51109 \| RDH11 \| DISEASES 55835 \| CENPJ \| DISEASES 114899 \| C1QTNF3 \| DISEASES 124220 \| ZG16B \| DISEASES 250 \| ALPP \| DISEASES 51466 \| EVL \| DISEASES 6152 \| RPL24 \| DISEASES 5530 \| PPP3CA \| DISEASES 2160 \| F11 \| DISEASES 279 \| AMY2A \| DISEASES 84148 \| KAT8 \| DISEASES 133396 \| IL31RA \| DISEASES 6999 \| TDO2 \| DISEASES 820 \| CAMP \| DISEASES 102723508 \| KANTR \| DISEASES 79104 \| MEG8 \| DISEASES
Locus	(Waiting for update.)

Disease ID	1361
Disease	thrombophlebitis
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:27) HP:0012531 \| Pain \| 2 HP:0002625 \| Blood clot in a deep vein \| 2 HP:0100806 \| Sepsis \| 2 HP:0002617 \| Aneurysmal dilatation \| 2 HP:0002204 \| Pulmonary embolism \| 1 HP:0004936 \| Blood clot in vein \| 1 HP:0001028 \| Strawberry mark \| 1 HP:0003401 \| Paresthesia \| 1 HP:0002894 \| Neoplasia of the pancreas \| 1 HP:0000618 \| Blindness \| 1 HP:0100658 \| Bacterial infection of skin \| 1 HP:0012089 \| Arteritis \| 1 HP:0030157 \| Flank pain \| 1 HP:0000964 \| Eczema \| 1 HP:0001945 \| Fever \| 1 HP:0030248 \| Blood clot in mesentertic vein \| 1 HP:0000246 \| Sinus inflammation \| 1 HP:0005293 \| Venous insufficiency \| 1 HP:0100523 \| Hepatic abscess \| 1 HP:0002754 \| Bone infection \| 1 HP:0000980 \| Pallor \| 1 HP:0001048 \| Cavernous angioma \| 1 HP:0030731 \| Carcinoma \| 1 HP:0000953 \| Hyperpigmentation of the skin \| 1 HP:0100758 \| Gangrene \| 1 HP:0012418 \| Low blood oxygen level \| 1 HP:0000265 \| Mastoiditis \| 1

Disease ID	1361
Disease	thrombophlebitis
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:4) C0036690 \| sepsis \| 2 C0030193 \| pain \| 2 C0017086 \| gangrene \| 1 C0034065 \| pulmonary embolism \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:15)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0040046	ciprofloxacin	D002939	85721-33-1	thrombophlebitis	MESH:D013924	marker/mechanism	3428012
C0040046	cyclophosphamide	D003520	50-18-0	thrombophlebitis	MESH:D013924	marker/mechanism	17461902
C0040046	desogestrel	D017135	54024-22-5	thrombophlebitis	MESH:D013924	marker/mechanism	7750278
C0040046	dicloxacillin	D004009	3116-76-5	thrombophlebitis	MESH:D013924	marker/mechanism	7064681
C0040046	epirubicin	D015251	56420-45-2	thrombophlebitis	MESH:D013924	marker/mechanism	17461902
C0040046	etomidate	D005045	33125-97-2	thrombophlebitis	MESH:D013924	marker/mechanism	2178488
C0040046	fluorouracil	D005472	51-21-8	thrombophlebitis	MESH:D013924	marker/mechanism	14553886
C0040046	leucovorin	D002955	1958/5/9	thrombophlebitis	MESH:D013924	marker/mechanism	15452397
C0040046	lorazepam	D008140	846-49-1	thrombophlebitis	MESH:D013924	marker/mechanism	25030
C0040046	methohexital	D008723	18652-93-2	thrombophlebitis	MESH:D013924	marker/mechanism	4897470
C0040046	octreotide	D015282	83150-76-9	thrombophlebitis	MESH:D013924	marker/mechanism	2793386
C0040046	sodium tetradecyl sulfate	D012981	1191-50-0	thrombophlebitis	MESH:D013924	marker/mechanism	6497633
C0040046	thiopental	D013874	76-75-5	thrombophlebitis	MESH:D013924	marker/mechanism	4635835
C0040046	vancomycin	D014640	1404-90-6	thrombophlebitis	MESH:D013924	marker/mechanism	3934126
C0040046	vitamin e	D014810	1406-18-4	thrombophlebitis	MESH:D013924	marker/mechanism	15562867

FDA approved drug and dosage information(Total Drugs:2)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D013924	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D013924	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No

FDA labeling changes(Total Drugs:2)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D013924	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D013924	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'

Web
Analytics